Integrated transcriptomics identifies a high-glycolysis osteosarcoma phenotype and links SSR3 to stemness and chemoresistance

Man, Yu-Nan, Sun, Wu, Sun, Yu, He, Mao-Lin, Liu, Ya-yun
npj Systems Biology and Applications · Springer Nature · 2026-10-28 · DOI: 10.1038/s41540-026-00842-9

Аннотация

Osteosarcoma treatment is hampered by intratumoral metabolic heterogeneity. We analyzed single‑cell and spatial transcriptomic data from 27 patients and stratified malignant cells into high- (HGlyOS), medium-, and low-glycolysis groups. HGlyOS cells exhibited enhanced stemness and chemotherapy resistance features and occupied an early inferred transcriptional state. Using nested machine learning across datasets, we derived a 34-gene Glycolysis activity Prediction System (GGPS) as a parsimonious proxy for the Composite Glycolytic Activity Score (CGAS)-defined glycolytic phenotype rather than as an independent subtype classifier. Through a separate screening pipeline combining co‑expression network analysis, differential expression, and machine learning, followed by literature mining, we identified SSR3 (which was not part of the 34‑gene signature) as a previously unreported glycolysis regulator in osteosarcoma. Independent functional experiments confirmed that SSR3 modulates glycolytic metabolism, stemness maintenance, and cisplatin sensitivity. Our work provides a metabolic classification framework for osteosarcoma and a proof‑of‑concept tool for single‑cell glycolytic phenotyping.

Читать у издателя →

Похожие статьи